Dr. Tam is a Clinical Associate Professor at the University of Calgary and a staff medical oncologist at the Arthur J. E. Child Comprehensive Cancer Centre who specializes in the treatment of gastrointestinal malignancies. Dr. Tam completed his medical training at the University of Ottawa, McMaster University and University of Toronto. His academic interests include hepatobiliary cancer clinical trials and real-world evidence research. Dr. Tam has been involved as an investigator on a number of phase II and III hepatobiliary clinical trials and currently chairs the CHORD Consortium Canadian Hepatocellular Carcinoma Database. Dr. Tam is also currently the co-chair of the Canadian Cancer Trials Group Hepatobiliary Disease Oriented Group and a member of the National Cancer Institute Hepatobiliary Task Force.
Tam, Vincent
Medical Oncology
Clinical Associate Professor
MD, BSc(Hon), FRCPC
Biography
Area of Focus
Hepatobiliary cancer clinical trials and real-world evidence research
Summary of Research
Key publications:
- Rimassa L, Chan SL, Sangro B, Lau G, Kudo M, Reig M, Breder V, Ryu MH, Ostapenko Y, Sukeepaisarnjaroen W, Varela M, Tougeron D, Crysler O, Bouattour M, Dao TV, Tam VC, Faccio A, Furuse J, Jeng LB, Kang YK, Kelley RK, Paskow MJ, Ran D, Xynos I, Kurland JF, Negro A, Abou-Alfa GK. Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC. Journal of Hepatology. 2025 October; 83(4): 899-908.
- Amaro CP, Lim CA, Ding PQ, Cheung WY, Syed I, Kim YJ, Shephard C, Wang S, Clouthier DL, Tam VC. A retrospective database analysis to understand treatment patterns and outcomes of intermediate and advanced hepatocellular carcinoma in Alberta, Canada (A-CAPTAIN Study). J Gastrointest Oncol. 2025 Apr 30;16(2):650-659.
- Lee CL, Freeman M, Burak KW, Moffat GT, O’Donnell C, Ding PQ, Lyubetska H, Meyers BM, Gordon V, Ekaterina K, Kay A, Bucur R, Cheung WY, Knox JJ, Tam VC. Real-World Outcomes of Atezolizumab with Bevacizumab Treatment in Hepatocellular Carcinoma Patients: Effectiveness, Esophagogastroduodenoscopy Utilization and Bleeding Complications. Senior Responsible Author. Cancers. 2024 Aug 19;16(16), 2878.
- Abou-Alfa GK, Chan SL, Kudo M, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Tu DV, de Toni E, Rimassa L, Breder V, Vasilyev A, Heurgué A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T Azevedo S, Calvo MV, Cheng AL, Qin S, Galle P, Marcovitz M, Makowsky M, He P, Kurland JF, Negro A, Sangro B. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. New England Journal of Medicine Evidence.
Area Of Focus
Hepatobiliary cancer clinical trials and real-world evidence research
Summary Of Research
Key publications:
- Rimassa L, Chan SL, Sangro B, Lau G, Kudo M, Reig M, Breder V, Ryu MH, Ostapenko Y, Sukeepaisarnjaroen W, Varela M, Tougeron D, Crysler O, Bouattour M, Dao TV, Tam VC, Faccio A, Furuse J, Jeng LB, Kang YK, Kelley RK, Paskow MJ, Ran D, Xynos I, Kurland JF, Negro A, Abou-Alfa GK. Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC. Journal of Hepatology. 2025 October; 83(4): 899-908.
- Amaro CP, Lim CA, Ding PQ, Cheung WY, Syed I, Kim YJ, Shephard C, Wang S, Clouthier DL, Tam VC. A retrospective database analysis to understand treatment patterns and outcomes of intermediate and advanced hepatocellular carcinoma in Alberta, Canada (A-CAPTAIN Study). J Gastrointest Oncol. 2025 Apr 30;16(2):650-659.
- Lee CL, Freeman M, Burak KW, Moffat GT, O’Donnell C, Ding PQ, Lyubetska H, Meyers BM, Gordon V, Ekaterina K, Kay A, Bucur R, Cheung WY, Knox JJ, Tam VC. Real-World Outcomes of Atezolizumab with Bevacizumab Treatment in Hepatocellular Carcinoma Patients: Effectiveness, Esophagogastroduodenoscopy Utilization and Bleeding Complications. Senior Responsible Author. Cancers. 2024 Aug 19;16(16), 2878.
- Abou-Alfa GK, Chan SL, Kudo M, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Tu DV, de Toni E, Rimassa L, Breder V, Vasilyev A, Heurgué A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T Azevedo S, Calvo MV, Cheng AL, Qin S, Galle P, Marcovitz M, Makowsky M, He P, Kurland JF, Negro A, Sangro B. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. New England Journal of Medicine Evidence.